These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1505560)

  • 1. A double-blind, parallel-group comparison of flosequinan and enalapril in the treatment of chronic heart failure.
    Silke B; Tennet H; Fischer-Hansen J; Keller N; Heikkila J; Salminen K
    Eur Heart J; 1992 Aug; 13(8):1092-100. PubMed ID: 1505560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of flosequinan on exercise capacity and cardiac function in patients with chronic mild heart failure: a double-blind placebo-controlled study.
    Hori M; Sato H; Ozaki H; Inoue M; Naka M; Fukunami M; Fukushima M; Kunisada K
    Heart Vessels; 1992; 7(3):133-40. PubMed ID: 1500398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Flosequinan in chronic heart failure: how is exercise capacity improved?
    Banning AP; Ramsey MW; Jones EA; Evans W; Carolan G; Jones CH; Henderson AH
    Eur J Clin Pharmacol; 1996; 51(2):133-8. PubMed ID: 8911877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic vasodilator therapy with flosequinan in congestive heart failure.
    Haas GJ; Binkley PE; Leier CV
    Clin Cardiol; 1990 Jun; 13(6):414-20. PubMed ID: 2188766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of flosequinan on exercise capacity and symptoms in severe heart failure.
    Elborn JS; Stanford CF; Nicholls DP
    Br Heart J; 1989 Apr; 61(4):331-5. PubMed ID: 2653391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Haemodynamic and neurohumoral effects of flosequinan in severe heart failure: similarities and differences compared with intravenous nitroglycerin therapy.
    Dakak N; Makhoul N; Merdler A; Yechiely H; Kahana L; Halon DA; Schneeweiss A; Lewis BS
    Eur Heart J; 1993 Jun; 14(6):836-44. PubMed ID: 8325314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A non-invasive evaluation of flosequinan on haemodynamics and exercise capacity in chronic congestive heart failure.
    Motro M; Freimark D; Feinberg MS; Wynne RD; King C; Schneeweiss A
    Int J Clin Pharmacol Res; 1993; 13(3):143-9. PubMed ID: 8225697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Effects of Flosequinan on the Morbidity and Mortality of Patients With Severe Chronic Heart Failure: Primary Results of the PROFILE Trial After 24 Years.
    Packer M; Pitt B; Rouleau JL; Swedberg K; DeMets DL; Fisher L
    JACC Heart Fail; 2017 Jun; 5(6):399-407. PubMed ID: 28501522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can further benefit be achieved by adding flosequinan to patients with congestive heart failure who remain symptomatic on diuretic, digoxin, and an angiotensin converting enzyme inhibitor? Results of the flosequinan-ACE inhibitor trial (FACET).
    Massie BM; Berk MR; Brozena SC; Elkayam U; Plehn JF; Kukin ML; Packer M; Murphy BE; Neuberg GW; Steingart RM
    Circulation; 1993 Aug; 88(2):492-501. PubMed ID: 8339411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-blind, placebo-controlled study of the efficacy of flosequinan in patients with chronic heart failure. Principal Investigators of the REFLECT Study.
    Packer M; Narahara KA; Elkayam U; Sullivan JM; Pearle DL; Massie BM; Creager MA
    J Am Coll Cardiol; 1993 Jul; 22(1):65-72. PubMed ID: 8509565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of assessing changes in ventricular response to atrial fibrillation during evaluation of new heart failure therapies: experience from trials of flosequinan.
    Massie BM; Shah NB; Pitt B; Packer M
    Am Heart J; 1996 Jul; 132(1 Pt 1):130-6. PubMed ID: 8701855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute and chronic effects of flosequinan on resting and exercise haemodynamics in congestive heart failure.
    Thomas P; O'Gorman DJ; Sheridan DJ
    Br J Clin Pharmacol; 1993 Dec; 36(6):539-46. PubMed ID: 12959270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurohormonal activation in severe heart failure: relations to patient death and the effect of treatment with flosequinan.
    Moe GW; Rouleau JL; Charbonneau L; Proulx G; Arnold JM; Hall C; de Champlain J; Barr A; Sirois P; Packer M
    Am Heart J; 2000 Apr; 139(4):587-95. PubMed ID: 10740139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flosequinan in heart failure: acute haemodynamic and longer term symptomatic effects.
    Cowley AJ; Wynne RD; Stainer K; Fullwood L; Rowley JM; Hampton JR
    BMJ; 1988 Jul; 297(6642):169-73. PubMed ID: 3044507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cumulative hemodynamic response to short-term treatment with flosequinan (BTS 49465), a new direct-acting vasodilator drug, in severe chronic congestive heart failure.
    Kessler PD; Packer M; Medina N; Yushak M
    J Cardiovasc Pharmacol; 1988 Jul; 12(1):6-11. PubMed ID: 2459536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of the effects of captopril and flosequinan in patients with severe heart failure.
    Cowley AJ; Wynne RD; Swami A; Birkhead J; Skene A; Hampton JR
    Cardiovasc Drugs Ther; 1992 Oct; 6(5):465-70. PubMed ID: 1450090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy of flosequinan in heart failure.
    Cowley AJ
    Am Heart J; 1991 Mar; 121(3 Pt 1):983-8. PubMed ID: 2000777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term vasodilator treatment with flosequinan does not lead to hemodynamic tolerance or neurohormonal activation in severe heart failure.
    Bartels GL; Remme WJ; Look MP; Kruijssen DA
    J Card Fail; 1995 Mar; 1(2):117-25. PubMed ID: 9420641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the safety and efficacy of delapril with enalapril in patients with congestive heart failure.
    Rengo F; Acanfora D; Furgi G; Papa A; Nicolino A; Picone C; Vitale DF; Rengo C
    Am J Cardiol; 1995 Jun; 75(18):25F-28F. PubMed ID: 7778530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy and safety of pimobendan in moderate heart failure. A double-blind parallel 6-month comparison with enalapril. The Pimobendan-Enalapril Study Group.
    Remme WJ; Krayenbühl HP; Baumann G; Frick MH; Haehl M; Nehmiz G; Baiker W
    Eur Heart J; 1994 Jul; 15(7):947-56. PubMed ID: 7925517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.